Skip to main content

Table 3 Model building steps

From: A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2genes based on cancer family history

  Number of parameters Akaike information criterion
   Both BRCA1 and BRCA2 BRCA1 BRCA2
Intercept 1 86.76 47.38 40.30
Sex 2 86.60 48.11 40.35
Proband breast cancer or ovarian cancer 2 87.75 48.37 41.22
Proband breast cancer 2 87.65 48.16 41.30
Proband bilateral breast cancer 2 87.62 48.32 41.06
Proband ovarian cancer 2 85.49 46.84 40.57
Family affected 2 86.19 45.05 41.29
Number of first-degree and second-degree relativesa 2 87.45 47.93 41.26
Total number of family members affecteda 2 85.13 47.99 38.40
Proportion of family members affecteda 2 86.99 48.30 40.32
Total number of tumors (including bilateral) 2 83.58 47.93 36.24
Total number of breast tumors 2 87.46 47.82 38.90
Number of persons with bilateral cancer 2 87.23 48.17 38.61
Total number of ovarian tumors (tnot) 2 74.76 38.08 38.04
Number of persons with ovarian and/or breast tumors (nbot) 2 83.17 46.35 38.29
BRCAPRO score 2 67.36 35.90 33.74
Myriad score 2 69.17 36.84 34.25
Age at diagnosis (diag) 2 82.38 42.44 40.72
BRCAPRO + Myriad 3 66.30 35.55 33.30
BRCAPRO + Myriad + tnot 4 64.58 34.32 -
BRCAPRO + Myriad + tnot + diag 5 62.46 29.10 -
BRCAPRO + Myriad + tnot + diag + BRCAPRO:diag 6 - 28.29 -
BRCAPRO + tnot + diag + BRCAPRO:diag 5 - 27.51 -
BRCAPRO + Myriad + nbot 4 - - 33.16
  1. Bold numbers represent the univariate and multiple regression models with the lowest Akaike information criterion. Italic numbers represent univariate regressions models with Akaike information criterion lower than that of the corresponding model. aAffected families only.